November 09, 2015 (Shareholders Foundation) - An investigation on behalf of current long-term investors in shares of Horizon Pharma PLC (NASDAQ:HZNP) was announced over potential breaches of fiduciary duties by certain officers and directors at Horizon Pharma.

The investigation by a law firm concerns whether certain Horizon Pharma officers and directors breached their fiduciary duties and caused damage to the company and its shareholders.
Horizon Pharma PLC (NASDAQ:HZNP reported that its annual Total Revenue rose from $18.84 million in 2012 to $296.95 million in 2014 while its Net Loss increased from $87.79 million in 2012 to $263.60 million in 2014.

On October 19, 2015, an article entitled Drug Makers Sidestep Barriers on Pricing was published noting that certain drug manufacturers, including Horizon Pharma PLC, have begun using specialty pharmacies to circumvent efforts of insurers and pharmacists to switch patients to generic components, or even to the over-the-counter versions. According to the article, Horizon Pharma PLC urges doctors to submit prescriptions to a mail-order specialty pharmacy affiliated with the drug company, rather than sending patients directly to the drugstore. The article further represents that Horizon Pharma PLCs use of specialty pharmacies allows Horizon Pharma PLC to charge inflated prices for prescriptions.